AIM vs. PASG, ATRA, TIL, AVRO, CVM, DYAI, TSBX, CRIS, GNTA, and TARA
Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Passage Bio (PASG), Atara Biotherapeutics (ATRA), Instil Bio (TIL), AVROBIO (AVRO), CEL-SCI (CVM), Dyadic International (DYAI), Turnstone Biologics (TSBX), Curis (CRIS), Genenta Science (GNTA), and Protara Therapeutics (TARA). These companies are all part of the "biological products, except diagnostic" industry.
Passage Bio (NASDAQ:PASG) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings.
AIM ImmunoTech has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
In the previous week, Passage Bio had 1 more articles in the media than AIM ImmunoTech. MarketBeat recorded 2 mentions for Passage Bio and 1 mentions for AIM ImmunoTech. AIM ImmunoTech's average media sentiment score of 0.54 beat Passage Bio's score of 0.00 indicating that Passage Bio is being referred to more favorably in the media.
AIM ImmunoTech received 8 more outperform votes than Passage Bio when rated by MarketBeat users. Likewise, 82.35% of users gave AIM ImmunoTech an outperform vote while only 66.67% of users gave Passage Bio an outperform vote.
Passage Bio has a net margin of 0.00% compared to Passage Bio's net margin of -16,123.32%. AIM ImmunoTech's return on equity of -68.53% beat Passage Bio's return on equity.
Passage Bio has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.36, meaning that its share price is 136% less volatile than the S&P 500.
Passage Bio currently has a consensus price target of $9.00, suggesting a potential upside of 659.49%. Given AIM ImmunoTech's higher probable upside, equities research analysts plainly believe Passage Bio is more favorable than AIM ImmunoTech.
53.5% of Passage Bio shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 4.3% of Passage Bio shares are held by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Passage Bio beats AIM ImmunoTech on 10 of the 16 factors compared between the two stocks.
Get AIM ImmunoTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIM ImmunoTech Competitors List
Related Companies and Tools
